SEC Company Response from Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690) (LRMR) — Nov 18, 2022
Larimar Therapeutics, Inc. (LRMR) (CIK 0001374690)
Date: Nov. 18, 2022 · CIK: 0001374690 · Accession: 0001193125-22-288978
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268312
Letter
Larimar Therapeutics, Inc.
Three Bala Plaza East, Suite 506
Bala Cynwyd, Pennsylvania 19004
November 18, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-7553
Re: Larimar Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 10, 2022 (File No. 333-268312)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-268312) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 PM, Eastern Time, on November 21, 2022, or as soon thereafter as is practicable.
Please contact Jennifer L. Porter, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4339 to provide notice of effectiveness, or if you have any questions or comments concerning this request.
[Remainder of the page intentionally left blank]
Very truly yours,
LARIMAR THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Larimar Therapeutics, Inc. Three Bala Plaza East, Suite 506 Bala Cynwyd, Pennsylvania 19004 November 18, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Larimar Therapeutics, Inc. Registration Statement on Form S-3 Filed November 10, 2022 (File No. 333-268312) Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Larimar Therapeutics, Inc. (the “Company”) hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-268312) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:01 PM, Eastern Time, on November 21, 2022, or as soon thereafter as is practicable. Please contact Jennifer L. Porter, Esq. of Troutman Pepper Hamilton Sanders LLP, counsel to the Company, at (215) 981-4339 to provide notice of effectiveness, or if you have any questions or comments concerning this request. [Remainder of the page intentionally left blank] Very truly yours, LARIMAR THERAPEUTICS, INC. By: /s/ Carole Ben-Maimon, M.D. Name: Carole Ben-Maimon, M.D. Title: President and Chief Executive Officer